168 related articles for article (PubMed ID: 22005648)
1. Favorable outcomes in patients with high donor-derived T cell count after in vivo T cell-depleted reduced-intensity allogeneic stem cell transplantation.
Toor AA; Sabo RT; Chung HM; Roberts C; Manjili RH; Song S; Williams DC; Edmiston W; Gatesman ML; Edwards RW; Ferreira-Gonzalez A; Clark WB; Neale MC; McCarty JM; Manjili MH
Biol Blood Marrow Transplant; 2012 May; 18(5):794-804. PubMed ID: 22005648
[TBL] [Abstract][Full Text] [Related]
2. Complete donor T cell chimerism predicts lower relapse incidence after standard double umbilical cord blood reduced-intensity conditioning regimen allogeneic transplantation in adults.
Peterlin P; Delaunay J; Guillaume T; Gastinne T; Mahé B; Dubruille V; Blin N; Le Bourgeois A; Brissot E; Lodé L; Le Gouill S; Moreau P; Mohty M; Chevallier P
Biol Blood Marrow Transplant; 2015 Jan; 21(1):180-4. PubMed ID: 25175796
[TBL] [Abstract][Full Text] [Related]
3. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up of persisting mixed chimerism after partially T cell-depleted allogeneic stem cell transplantation.
Schaap N; Schattenberg A; Mensink E; Preijers F; Hillegers M; Knops R; Pennings A; Boezeman J; Geurts van Kessel A; de Pauw B; de Witte T
Leukemia; 2002 Jan; 16(1):13-21. PubMed ID: 11840258
[TBL] [Abstract][Full Text] [Related]
5. Donor lymphocyte infusion for relapsed hematological malignancies after allogeneic hematopoietic cell transplantation: prognostic relevance of the initial CD3+ T cell dose.
Bar M; Sandmaier BM; Inamoto Y; Bruno B; Hari P; Chauncey T; Martin PJ; Storb R; Maloney DG; Storer B; Flowers ME
Biol Blood Marrow Transplant; 2013 Jun; 19(6):949-57. PubMed ID: 23523892
[TBL] [Abstract][Full Text] [Related]
6. Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation.
Dey BR; McAfee S; Colby C; Sackstein R; Saidman S; Tarbell N; Sachs DH; Sykes M; Spitzer TR
Biol Blood Marrow Transplant; 2003 May; 9(5):320-9. PubMed ID: 12766882
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
[TBL] [Abstract][Full Text] [Related]
8. Donor chimerism early after reduced-intensity conditioning hematopoietic stem cell transplantation predicts relapse and survival.
Koreth J; Kim HT; Nikiforow S; Milford EL; Armand P; Cutler C; Glotzbecker B; Ho VT; Antin JH; Soiffer RJ; Ritz J; Alyea EP
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1516-21. PubMed ID: 24907627
[TBL] [Abstract][Full Text] [Related]
9. Minimal GVHD following in-vitro T cell-depleted allogeneic stem cell transplantation with reduced-intensity conditioning allowing subsequent infusions of donor lymphocytes in patients with hematological malignancies and solid tumors.
Barge RM; Osanto S; Marijt WA; Starrenburg CW; Fibbe WE; Nortier JW; Falkenburg JH; Willemze R
Exp Hematol; 2003 Oct; 31(10):865-72. PubMed ID: 14550801
[TBL] [Abstract][Full Text] [Related]
10. Acute GVHD is a strong predictor of full donor CD3+ T cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation.
El-Cheikh J; Vazquez A; Crocchiolo R; Furst S; Calmels B; Castagna L; Lemarie C; Granata A; Ladaique P; Oudin C; Faucher C; Chabannon C; Blaise D
Am J Hematol; 2012 Dec; 87(12):1074-8. PubMed ID: 22911907
[TBL] [Abstract][Full Text] [Related]
11. TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors.
Kohrt HE; Turnbull BB; Heydari K; Shizuru JA; Laport GG; Miklos DB; Johnston LJ; Arai S; Weng WK; Hoppe RT; Lavori PW; Blume KG; Negrin RS; Strober S; Lowsky R
Blood; 2009 Jul; 114(5):1099-109. PubMed ID: 19423725
[TBL] [Abstract][Full Text] [Related]
12. Prospective phase II trial to evaluate the complications and kinetics of chimerism induction following allogeneic hematopoietic stem cell transplantation with fludarabine and busulfan.
Saito AM; Kami M; Mori S; Kanda Y; Suzuki R; Mineishi S; Takami A; Taniguchi S; Takemoto Y; Hara M; Yamaguchi M; Hino M; Yoshida T; Kim SW; Hori A; Ohashi Y; Takaue Y
Am J Hematol; 2007 Oct; 82(10):873-80. PubMed ID: 17570513
[TBL] [Abstract][Full Text] [Related]
13. Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies.
Hamadani M; Blum W; Phillips G; Elder P; Andritsos L; Hofmeister C; O'Donnell L; Klisovic R; Penza S; Garzon R; Krugh D; Lin T; Bechtel T; Benson DM; Byrd JC; Marcucci G; Devine SM
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1422-30. PubMed ID: 19822302
[TBL] [Abstract][Full Text] [Related]
14. The influence of lymphoid reconstitution kinetics on clinical outcomes in allogeneic stem cell transplantation.
Kobulnicky DJ; Sabo RT; Sharma S; Shubar Ali AS; Kobulnicky KM; Roberts CH; Clark WB; Chung HM; McCarty JM; Toor AA
Leuk Lymphoma; 2018 Dec; 59(12):2973-2981. PubMed ID: 29616870
[TBL] [Abstract][Full Text] [Related]
15. Preemptive DLI without withdrawal of immunosuppression to promote complete donor T-cell chimerism results in favorable outcomes for high-risk older recipients of alemtuzumab-containing reduced-intensity unrelated donor allogeneic transplant: a prospective phase II trial.
Solomon SR; Sizemore CA; Zhang X; Brown S; Holland HK; Morris LE; Bashey A
Bone Marrow Transplant; 2014 May; 49(5):616-21. PubMed ID: 24801098
[TBL] [Abstract][Full Text] [Related]
16. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update.
Bethge WA; Faul C; Bornhäuser M; Stuhler G; Beelen DW; Lang P; Stelljes M; Vogel W; Hägele M; Handgretinger R; Kanz L
Blood Cells Mol Dis; 2008; 40(1):13-9. PubMed ID: 17869547
[TBL] [Abstract][Full Text] [Related]
17. Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies.
Spitzer TR; McAfee S; Sackstein R; Colby C; Toh HC; Multani P; Saidman S; Weyouth DW; Preffer F; Poliquin C; Foley A; Cox B; Andrews D; Sachs DH; Sykes M
Biol Blood Marrow Transplant; 2000; 6(3A):309-20. PubMed ID: 10905768
[TBL] [Abstract][Full Text] [Related]
18. Donor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: a dose-escalation study.
Choi I; Yoon SR; Park SY; Kim H; Jung SJ; Jang YJ; Kang M; Yeom YI; Lee JL; Kim DY; Lee YS; Kang YA; Jeon M; Seol M; Lee JH; Lee JH; Kim HJ; Yun SC; Lee KH
Biol Blood Marrow Transplant; 2014 May; 20(5):696-704. PubMed ID: 24525278
[TBL] [Abstract][Full Text] [Related]
19. Dynamical System Modeling of Immune Reconstitution after Allogeneic Stem Cell Transplantation Identifies Patients at Risk for Adverse Outcomes.
Toor AA; Sabo RT; Roberts CH; Moore BL; Salman SR; Scalora AF; Aziz MT; Shubar Ali AS; Hall CE; Meier J; Thorn RM; Wang E; Song S; Miller K; Rizzo K; Clark WB; McCarty JM; Chung HM; Manjili MH; Neale MC
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1237-45. PubMed ID: 25849208
[TBL] [Abstract][Full Text] [Related]
20. Reduced-intensity conditioning allogeneic hematopoietic cell transplantation for patients with hematologic malignancies who relapse following autologous transplantation: a multi-institutional prospective study from the Cancer and Leukemia Group B (CALGB trial 100002).
Bashey A; Owzar K; Johnson JL; Edwards PS; Kelly M; Baxter-Lowe LA; Devine S; Farag S; Hurd D; Ball E; McCarthy P; Lister J; Shea TC; Linker C
Biol Blood Marrow Transplant; 2011 Apr; 17(4):558-65. PubMed ID: 20674758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
